AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01224015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 44 U
Description: 44 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
Study NCT01224015 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: onabotulinumtoxinA 24 U
Description: 24 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
Study NCT03062332 — intervention group
Intervention type: GENETIC
Intervention: Faecal genome
Description: Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.
Study NCT03926442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Italian Herb meal
Description: Italian Herb in active breakfast meal
Study NCT03926442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cinnamon Meal
Description: Cinnamon in active breakfast meal
Study NCT03926442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pumpkin Spice meal
Description: Pumpkin Spice Mix in active breakfast meal
Study NCT03926442 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo meal
Description: Placebo in breakfast meal
Study NCT01499992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard physical therapy program PLUS aquatic physical therapy
Description: 2. Standard physical therapy program PLUS aquatic physical therapy: The above PLUS a aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focusing on the shoulder. The program will start with general mobility of the other upper limb joints to allow time for preconditioning of the painful shoulder. Shoulder exercises will emphasize flexion, rotation and abduction and a slow transition from pain-free range to the restricted range of motion to maximize the effectiveness of the heat and buoyancy.
Study NCT01499992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: Total of 12 weeks; each exercise session will be 20 -30 minutes of direct contact and additional supervised exercise as defined by assignment and stage.
Study NCT03427216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen/diazepam
Description: Vaginal suppository placed once daily, patients will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weekly
Study NCT03427216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal placebo
Description: Vaginal suppository placed once daily, patient will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weeky.
Study NCT03436277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: L-Carnitine oral solution 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
Study NCT03436277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sucralose
Description: Sucralose 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
Study NCT03051165 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hypoglossal Nerve Stimulation Treatment Withdrawal
Description: After 90 days of hypoglossal nerve stimulation (HGNS), therapy will be discontinued for 30 days before being reactivated.
Study NCT04751838 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT01896310 — intervention group
Intervention type: DEVICE
Intervention: probe-based confocal laser endomicroscopy
Description: all patients will receive pCLE examination
Study NCT03631953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib administered at a fixed dose (1.5 mg daily)
Study NCT03631953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: A panel of 3 doses of ALPELISIB could be tested
Study NCT03631953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Therapeutic biomarkers
Study NCT03631953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: A MRI with contrast will be performed before treatment start. Assessment of tumor growth.
Study NCT02847689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language Treatment
Description: Recording of a mother's voice reading a children's storybook.
Study NCT02847689 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Treatment
Description: Standard of Care
Study NCT02092116 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Romidepsin
Description: Latency reversing agent
Study NCT02092116 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vacc-4x
Description: Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
Study NCT02092116 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rhuGM-CSF
Description: Granulocyte macrophage colony stimulating factor as a local adjuvant
Study NCT00770757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-4047
Study NCT00739141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
Description: Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
Study NCT01264679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: IV Ferumoxytol
Study NCT03482011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC
Study NCT03482011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03074331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet(s) administered orally once daily
Study NCT02428179 — intervention group
Intervention type: PROCEDURE
Intervention: StOP? - Intervention group
Description: Intervention group - Surgical procedure with intraoperative briefings, optional interventions: Transparent drape between anesthesia and sterile team, Controlling noise and potential distractors during wound closure, Nutritional support during the operation
Study NCT03648814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracameral injection
Description: A/C injection of 1.25 mg/0.05 mL bevacizumab
Study NCT03648814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravitreal injection
Description: Vitreous injection of 1.25 mg/0.05 mL bevacizumab
Study NCT03050918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up Phone Call
Description: Patients will receive a first call attempt within 72 hours discharge.
Study NCT02265172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy screening
Description: Physiotherapy screening.
Study NCT03888248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Description: Home-based whole-body vibration therapy by standing on Galileo Med 15 platform for 9 mins twice a day for 5 days per week
Study NCT03888248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle strengthening exercises
Description: Daily muscle strengthening exercises to be performed at home following a group education session by paediatric physiotherapist
Study NCT03888248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strengthening exercises
Description: Daily muscle strengthening exercises to be performed at home following a group education session by paediatric physiotherapist
Study NCT01604161 — intervention group
Intervention type: DRUG
Intervention: somatropin
Description: Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
Study NCT02073578 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peroral Endoscopic Myotomy (POEM)
Description: Endoscopy myotomy for treatment of achalasia
Study NCT02137070 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric Surgery Candidates
Description: Participants who are intending to have bariatric surgery for weight loss
Study NCT02137070 — intervention group
Intervention type: OTHER
Intervention: Non surgical/Community volunteers
Description: Healthy adults with body mass index >35 who will not undergo bariatric surgery for weight loss
Study NCT02311725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aTAU + sTVi
Description: Antidepressant treatment as usual provided by participants' primary care physician plus narrative communication, video-based intervention for improving depression in primary care patients.
Study NCT02311725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aTAU + Attention Control Videos
Description: Antidepressant treatment as usual provided by participants' primary care physician plus videos about general mental health and well-being on the same dose and frequency as the experimental intervention.
Study NCT05035303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nor-Epinephrine injection versus saline during PCNL
Description: The PCNL tract is infiltrated by Nor-Epinephrine or Normal Saline before its dilatation.
Study NCT05035303 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nor-Epinephrine injection versus saline during PCNL
Description: The PCNL tract is infiltrated by Nor-Epinephrine or Normal Saline before its dilatation.
Study NCT01074567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMSO cocktail
Description: intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
Study NCT01319617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Description: Soft contact lens-based device intended for continuous recording of relative changes in IOP
Study NCT01595061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01595061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01595061 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT01595061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo local core biopsy or surgical excision
Study NCT00137995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m² D-2/D1
Study NCT00137995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m² D1-D2-D3
Study NCT00137995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatine
Description: max 800mg D2
Study NCT00137995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide + Mesna
Description: 5 g/m² from D2 to D13
Study NCT00137995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatine
Description: 100 mg/m² from D1 to D13
Study NCT02496481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing (MI) in the ED has been used to encourage a variety of health behaviors among at-risk patients. In this study, researchers will employ motivational interviewing with half of the study participants to investigate the effects of the technique on child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
Study NCT02496481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored brochure
Description: Tailored Print materials will be mailed to half of participants to investigate the effects of using patient-centered educational materials compared with generic educational materials to influence child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
Study NCT01635010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure (CPAP)
Description: CPAP pressure is individually prescript according to polysomnography for CPAP titration
Study NCT03810001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mechanical Stimulation
Description: micromanipulation technique before insertion of the microinjection needle into the oocyte and expulsion of the spermatozoon
Study NCT03647436 — intervention group
Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment. Both groups.
Description: Evaluation of the incidence of geriatric syndromes: depression, delirium, cognitive disorders, falls, gait disturbances, urinary and fecal incontinence
Study NCT01758965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPI
Description: monotherapy of PPI
Study NCT01758965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H2RA and surgicel
Description: combination therapy of H2RA and surgicel
Study NCT02131012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Celecoxib
Description: 1-4 mg intravitreal celecoxib
Study NCT06157047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crestal Bone Expansion obtained with the Magnetic Mallet®
Description: A magnetodynamic instrument (Magnetic Mallet®, Metaergonomica, Turbigo, Italy) has been used to perform a horizontal bone expansion in edentulous sites that need to be rehabilitated with a dental implant.
Study NCT01595659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passenger
Description: Driving with risk accepting or risk averse passenger
Study NCT01595659 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Passenger
Description: Driving with risk accepting or risk averse passenger
Study NCT02813759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Subjects drank 200 mL of water with 14 mg sucralose, followed by a standard breakfast.
Study NCT02813759 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects drank 200 mL of water alone (placebo), followed by a standard breakfast.
Study NCT02357797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine
Study NCT02357797 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02795546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate sodium
Description: 400µg of alendronate sodium is combined with beta-tricalcium phosphate bone graft and implanted in periodontal intra-osseous defects as a single, local dose.
Study NCT02795546 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: beta-tricalcium phosphate bone substitute
Description: beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.
Study NCT02795546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: beta-tricalcium phosphate bone substitute
Description: beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.
Study NCT02051725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active life-style intervention
Study NCT00399594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A
Description: LV lead placement in region of latest mechanical velocity (tissue doppler)
Study NCT00399594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: B
Description: LV lead placement in standard (lateral / posterolateral) position.
Study NCT00137995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytosine Arabinoside
Description: 2000 mg/m²/12 h D2 D3
Study NCT00137995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg From D1 to D4
Study NCT00137995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Study NCT00137995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 300mg/m² on D-6
Study NCT00137995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m² from D-6 to D-3
Study NCT00137995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m² from D-6 to D-3
Study NCT00137995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m² on D-2
Study NCT03125863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AquaBeam System
Description: The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
Study NCT02853565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN008
Description: The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
Study NCT00962702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAAx TigerPaw System
Description: Exclusion of Left Atrial Appendage
Study NCT04055246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: 9 grams of food grade inulin added to custom made fiber bars.
Study NCT04055246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (maltodextrin)
Description: 9 grams of food grade maltodextrin - replaces inulin in fiber bars.
Study NCT03777696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 μg of buccal misoprostol
Study NCT02265172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard practice
Description: Orthopaedic surgeon assessment
Study NCT00986570 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: 100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.
Study NCT02795637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasotraline
Description: dasotraline 8mg capsule/day
Study NCT00621036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous immunoglobulin idiotype-KLH conjugate vaccine
Study NCT00621036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00621036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00621036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Study NCT00621036 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02164630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hope Therapy
Description: Hope therapy is designed to address key components of hope theory through augmentation of hopeful thinking and enhancement of goal-directed activities. Training focuses on effective goal setting, mobilization of internal resources to reach goals, identification of resilience factors to formulate hopeful thinking, and enhancing maintenance of future goal development.
Study NCT02164630 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pain Education
Description: Pain Education is aimed to increase understanding of TMD symptomatology and etiology, as well as provide general education on pain, lifestyle management, and effective pain communication methods.
Study NCT01648504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eGuide to Colonoscopy and in office ipad education
Description: The investigators will follow patients who receive in office Ipad video education and at home web portal access to the Johns Hopkins eGuide to Colonoscopy.
Study NCT02546349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/salmeterol, tiotropium
Description: In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
Study NCT02546349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol, tiotropium
Description: In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
Study NCT03165877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-glycemic index
Description: Subjects ate low-glycemic index lunches and dinners (\<55%),consisting of salad, main course and dessert, respectively.